Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities (Tables)

v3.10.0.1
Accrued Expenses and Other Long-Term Liabilities (Tables)
9 Months Ended
Sep. 30, 2018
Components of Accrued Expenses and Other Long-Term Liabilities
Accrued expenses and other long-term liabilities, excluding National, consisted of the following:
 
 
 
September 30,
2018
 
 
December 31,
2017
 
Accrued Expenses:
 
 
 
 
 
 
 
 
Professional fees
 
$
1,471
 
 
$
1,625
 
Salaries, bonuses and related benefits
 
 
4,349
 
 
 
5,279
 
Accrued expenses - related party
 
 
50
 
 
 
95
 
Research and development
 
 
3,036
 
 
 
1,873
 
Milestones related to license agreement
 
 
2,500
 
 
 
800
 
Manufacturing
 
 
1,411
 
 
 
1,188
 
Clinical supplies
 
 
2,619
 
 
 
85
 
License maintenance fees
 
 
454
 
 
 
100
 
Dr. Falk Pharma milestone (See Note 16)
 
 
1,300
 
 
 
3,059
 
Accrued royalties payable
 
 
1,045
 
 
 
1,411
 
Deferred coupon funding
 
 
1,490
 
 
 
1,087
 
Other
 
 
644
 
 
 
1,030
 
Total accrued expenses
 
$
20,369
 
 
$
17,632
 
 
 
 
 
 
 
 
 
 
Other long-term liabilities:
 
 
 
 
 
 
 
 
Deferred rent and long-term lease abandonment charge
 
 
4,961
 
 
 
4,739
 
Total other long-term liabilities
 
$
4,961
 
 
$
4,739
 
National Holdings Corporation [Member]  
Components of Accrued Expenses and Other Long-Term Liabilities
National’s accounts payable and other accrued expenses as of June 30, 2018 and September 31, 2017, consisted of the following:
 
 
 
June 30, 2018
 
 
September 30, 2017
 
Legal
 
$
1,018
 
 
$
877
 
Audit
 
 
258
 
 
 
176
 
Telecommunications
 
 
207
 
 
 
205
 
Data Services
 
 
547
 
 
 
464
 
Regulatory
 
 
372
 
 
 
540
 
Settlements
 
 
487
 
 
 
2,403
 
Deferred rent
 
 
679
 
 
 
497
 
Other
 
 
3,135
 
 
 
3,242
 
Total
 
$
6,703
 
 
$
8,404